Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

52.88USD
2:18pm EDT
Change (% chg)

$-0.37 (-0.69%)
Prev Close
$53.25
Open
$53.21
Day's High
$53.54
Day's Low
$52.24
Volume
134,915
Avg. Vol
459,052
52-wk High
$80.03
52-wk Low
$31.39

ALNY.OQ

Chart for ALNY.OQ

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.87
Market Cap(Mil.): $4,582.30
Shares Outstanding(Mil.): 86.05
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 48.09 29.63
EPS (TTM): -4.79 -- --
ROI: -33.40 -2.54 13.01
ROE: -37.54 5.17 14.16

BRIEF-Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran

* Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran, an investigational rnai therapeutic for the treatment of acute hepatic porphyrias

Mar 01 2017

BRIEF-Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity

* Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity

Feb 08 2017

BRIEF-ALNYLAM PRESENTS NEW DATA ON FITUSIRAN AT EAHAD

* ALNYLAM PHARMACEUTICALS INC - ANNOUNCED NEW RESULTS FROM AN EXPLORATORY ANALYSIS OF ITS PHASE 1 STUDY WITH FITUSIRAN

Feb 02 2017

BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran

* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)

Nov 15 2016

BRIEF-Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision

* Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders

Nov 14 2016

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months

Nov 13 2016

BRIEF-Alnylam Pharmaceuticals reports Q3 loss per share $1.21 including items

* Alnylam pharmaceuticals reports third quarter 2016 financial results and highlights recent period activity

Nov 02 2016

BRIEF-Alnylam Pharmaceuticals -Data monitoring committee recommends continuation of Apollo phase 3 clinical trial of Patisiran

* Data monitoring committee recommends continuation of Apollo phase 3 clinical trial of patisiran for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

Oct 10 2016

Alnylam ends development of drug due to patient deaths in trial

Alnylam Pharmaceuticals Inc said on Wednesday it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure, after a late-stage study showed that patients given the drug were more likely to die than patients treated with a placebo.

Oct 05 2016

BRIEF-Alnylam Pharma says discontinues revusiran development

* Decision to discontinue development of revusiran does not affect patisiran

Oct 05 2016

More From Around the Web

Earnings vs. Estimates